Palsonify: Dosage Form, Projected Sales, NCE-1 Date | Paltusotine

Palsonify

Palsonify is an oral somatostatin receptor agonist approved for adults with acromegaly. It suppresses excess growth hormone and IGF-1 levels, providing a once-daily, non-injectable alternative to traditional therapies.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

Molecule Name :

Paltusotine
Innovator :

CRINETICS PHARMA INC
Approval Date :

25-Sep-25
NCE-1 Date :

25-Sep-29
NCE Date :

25-Sep-30
Dosage Form :

Oral Tablet
Strength :

20MG and 30MG
Therapeutic Category :

Hormonal Therapy
Revenue ($M) :

NA

Year-wise Projected Sales ($M) :

2025 :

5
2026 :

52
2027 :

121
2028 :

213
2029 :

346
2030 :

469
2031 :

621

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Palsonify

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?